Titleist Asset Management LLC Makes New $2.36 Million Investment in Tempus AI, Inc. $TEM

Key Points

• Titleist Asset Management LLC has made a significant investment of approximately $2.36 million in Tempus AI, purchasing 48,943 shares of the company during the first quarter.
• Tempus AI reported revenues of $314.64 million for the latest quarter, exceeding analyst estimates, and set its FY 2025 guidance while achieving an 89.5% year-over-year revenue increase.
• The consensus rating for Tempus AI's stock is "Moderate Buy," with a target price of $67.64 as analysts project growth despite the company’s challenge of negative earnings per share.

Titleist Asset Management LLC acquired a new position in Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 48,943 shares of the company's stock, valued at approximately $2,361,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. ARK Investment Management LLC raised its stake in Tempus AI by 35.9% during the 1st quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company's stock worth $361,867,000 after acquiring an additional 1,981,755 shares during the period. Vanguard Group Inc. raised its stake in Tempus AI by 6,247.5% during the 1st quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company's stock worth $289,204,000 after acquiring an additional 5,900,668 shares during the period. Nikko Asset Management Americas Inc. raised its stake in Tempus AI by 31.5% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company's stock worth $205,401,000 after acquiring an additional 1,021,460 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its stake in Tempus AI by 31.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock worth $205,284,000 after acquiring an additional 1,016,384 shares during the period. Finally, Frontier Capital Management Co. LLC raised its stake in Tempus AI by 236.2% during the 4th quarter. Frontier Capital Management Co. LLC now owns 943,718 shares of the company's stock worth $31,860,000 after acquiring an additional 663,018 shares during the period. Hedge funds and other institutional investors own 24.22% of the company's stock.

Insider Activity

In related news, CEO Eric P. Lefkofsky sold 332,500 shares of the company's stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $74.10, for a total value of $24,638,250.00. Following the completion of the sale, the chief executive officer directly owned 9,207,533 shares of the company's stock, valued at $682,278,195.30. This represents a 3.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Andrew Polovin sold 5,398 shares of the company's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total transaction of $402,960.70. Following the completion of the sale, the executive vice president directly owned 132,056 shares of the company's stock, valued at approximately $9,857,980.40. This trade represents a 3.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,108,951 shares of company stock valued at $77,660,938. Insiders own 26.27% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Bank of America lifted their price objective on shares of Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a research report on Wednesday, June 25th. Guggenheim lifted their price objective on shares of Tempus AI from $65.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, June 30th. Piper Sandler reiterated a "neutral" rating on shares of Tempus AI in a research report on Friday, August 8th. Needham & Company LLC restated a "buy" rating and issued a $70.00 price target on shares of Tempus AI in a research report on Friday, August 8th. Finally, BTIG Research boosted their price target on shares of Tempus AI from $75.00 to $85.00 and gave the stock a "buy" rating in a research report on Wednesday, August 20th. Seven analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $69.50.

Tempus AI Trading Up 3.2%

Shares of TEM traded up $2.40 during trading hours on Tuesday, reaching $78.26. 8,931,883 shares of the company traded hands, compared to its average volume of 12,454,320. The firm has a market cap of $13.60 billion, a price-to-earnings ratio of -65.76 and a beta of 5.07. Tempus AI, Inc. has a 12-month low of $31.36 and a 12-month high of $91.45. The company has a current ratio of 1.54, a quick ratio of 1.43 and a debt-to-equity ratio of 2.58. The stock's fifty day moving average price is $64.51 and its 200 day moving average price is $59.07.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. The firm had revenue of $314.64 million during the quarter, compared to analyst estimates of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The business's revenue was up 89.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($6.86) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.